Combination therapy with protease (PR) and reverse transcriptase (RT) inhibitors can
efficiently suppress human immunodeficiency virus (HIV) replication, but the emergence of …

Background: Development of drug resistance is one of the major reasons for the failure of
antiretroviral therapy of HIV-1 infection. Knowing the drug sensitivity–resistance profile of …

Human immunodeficiency virus type 1 (HIV-1) protease inhibitor-resistant variants, isolated
on passage of HIV-1HXB2 in MT-4 cells with five different protease inhibitors, have been …

In a sample of 6,156 sequences from 4,183 persons, the top 30 patterns of protease
inhibitor, nucleoside reverse transcriptase (RT) inhibitor, and nonnucleoside RT inhibitor …

There are 16 approved human immunodeficiency virus type 1 (HIV-1) drugs belonging to
three mechanistic classes: protease inhibitors, nucleoside and nucleotide reverse …

Mutations in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and
protease that confer resistance to antiretroviral agents are usually accompanied by a …

Objectives: To study the effect of the interruption of reverse transriptase inhibitor (RTI)
therapy or a switch from RTI to protease inhibitors, on the genotypic drug-resistance pattern …

We have developed a new recombinant retroviral system in which a library of infectious
molecular clones of human immunodeficiency virus type 1 (HIV-1) is constructed with …

Human immunodeficiency virus type 1 (HIV-1) variants resistant to protease (PR) and
reverse transcriptase (RT) inhibitors may display impaired infectivity and replication …

Objectives: To assess the in-vitro drug susceptibility of a panel of five well-characterized
drug-resistant HIV variants to recently developed anti-HIV compounds including seven …